Richard Dimelow

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Systemic Lupus Erythematosus

Top Venues

Journal of pharmacokinetics and pharmacodynamics

CPT: pharmacometrics & systems pharmacology

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Monica Simeoni, Shuying Yang, Debra J Tompson, Richard Dimelow
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Monica Simeoni, Shuying Yang, Debra J Tompson, Richard Dimelow
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Monica Simeoni, Shuying Yang, Debra J Tompson, Richard Dimelow
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Monica Simeoni, Shuying Yang, Debra J Tompson, Richard Dimelow
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Monica Simeoni, Shuying Yang, Debra J Tompson, Richard Dimelow
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab. Journal of pharmacokinetics and pharmacodynamics (2024)
Richard Dimelow, William R Gillespie, Andre van Maurik
Population model-based analysis of the memory B-cell response following belimumab therapy in the treatment of systemic lupus erythematosus. CPT: pharmacometrics & systems pharmacology (2023)
Disala Fernando, Richard Dimelow, Ciara Gorey, Xinyi Zhu, Catherine Muya, Connie Parker, Wayne Wright, Sara Soleman, Sarah Walsh, Madelein Crause, Georgios Vlasakakis, William Guiney, Nicola Robertson, Marylise Bergeal, Yi Cui, Alexander W Krug, Iain Uings
Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo-controlled first-in-human study in healthy volunteers. British journal of clinical pharmacology (2021)